3. Use of any of the following after transplantation and prior to starting study therapy for cohort 3: 1. Investigational agents/therapies. 2. Anti-leukemic agents given as post-transplant maintenance therapy (e.g., subcutaneous or oral 5-Azacytidine or FLT3 inhibitors for maintenance).